| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vision Disorders | D014786 | 10 associated lipids |
| Multiple Myeloma | D009101 | 13 associated lipids |
| Osteoporosis | D010024 | 12 associated lipids |
| Kidney Diseases | D007674 | 29 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Otosclerosis | D010040 | 2 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Hypersensitivity, Delayed | D006968 | 43 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Calcinosis | D002114 | 5 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sheng ZF et al. | Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. | 2009 | Osteoporos Int | pmid:18496637 |
| Xie H et al. | Omentin-1 exerts bone-sparing effect in ovariectomized mice. | 2012 | Osteoporos Int | pmid:21755404 |
| Nakashima A et al. | Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. | 2011 | Osteoporos Int | pmid:20812007 |
| Khosla S et al. | Correlates of osteoprotegerin levels in women and men. | 2002 | Osteoporos Int | pmid:12086350 |
| D'Amelio P et al. | Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. | 2011 | Osteoporos Int | pmid:21116815 |
| Li YF et al. | The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. | 2012 | Osteoporos Int | pmid:21892678 |
| Pennisi P et al. | Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. | 2004 | Osteoporos Int | pmid:14661073 |
| Jørgensen L et al. | Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. | 2010 | Osteoporos Int | pmid:19701599 |
| Ferrari-Lacraz S and Ferrari S | Do RANKL inhibitors (denosumab) affect inflammation and immunity? | 2011 | Osteoporos Int | pmid:20571772 |
| Kahl KG et al. | Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. | 2005 | Osteoporos Int | pmid:15300363 |
| Leder BZ and Finkelstein JS | Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. | 2005 | Osteoporos Int | pmid:15856361 |
| Simpson CA et al. | Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. | 2014 | Osteoporos Int | pmid:24927689 |
| Indridason OS et al. | Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. | 2005 | Osteoporos Int | pmid:15776220 |
| Fiore CE et al. | Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. | 2005 | Osteoporos Int | pmid:15983730 |
| Maïmoun L et al. | In peripubertal girls, artistic gymnastics improves areal bone mineral density and femoral bone geometry without affecting serum OPG/RANKL levels. | 2011 | Osteoporos Int | pmid:21359671 |
| Riggs BL et al. | Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. | 2003 | Osteoporos Int | pmid:12879223 |
| Hamed AA and Fayad JN | Presence of otosclerosis and paget lesions in the same temporal bone. | 2009 | Otol. Neurotol. | pmid:19779387 |
| Kuczkowski J et al. | [Molecular control of bone resorption in chronic otitis media with cholesteatoma]. | 2010 Jul-Aug | Otolaryngol Pol | pmid:20873097 |
| Cervellati C et al. | Higher Urinary Levels of 8-Hydroxy-2'-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with Osteopenia. | 2016 | Oxid Med Cell Longev | pmid:26635910 |
| Songia P et al. | Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model. | 2017 | Oxid Med Cell Longev | pmid:28261377 |
| Heitzer E et al. | IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer. | 2012 Nov-Dec | Pain Physician | pmid:23159968 |
| Satoh K et al. | Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. | 2001 | Pancreas | pmid:11590320 |
| Pietrapertosa AC et al. | Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. | 2009 | Panminerva Med | pmid:19352306 |
| Gulseren A et al. | Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin. | 2011 | Panminerva Med | pmid:21659972 |
| D'Amore M et al. | Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women. | 2006 | Panminerva Med | pmid:17215793 |
| Michou L et al. | [Molecular analysis of Paget's disease of bone]. | 2007 Apr-May | Pathol. Biol. | pmid:16884862 |
| Ikeda T et al. | Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. | 2003 | Pathol. Int. | pmid:12828610 |
| Quan J et al. | Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. | 2012 | Pathology | pmid:22406484 |
| Won KY et al. | RANK signalling in bone lesions with osteoclast-like giant cells. | 2011 | Pathology | pmid:21532526 |
| Levidou G et al. | TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. | 2013 | Pathology | pmid:23277172 |
| Chan MH et al. | Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. | 2005 | Pathology | pmid:15875734 |
| Ishii R et al. | High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. | 2006 | Pediatr Blood Cancer | pmid:16358318 |
| Skordis N et al. | Hormonal dysregulation and bones in thalassaemia--an overview. | 2008 | Pediatr Endocrinol Rev | pmid:19337163 |
| Angelopoulos NG et al. | Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. | 2007 Oct-Nov | Pediatr Hematol Oncol | pmid:17786784 |
| Rianthavorn P et al. | Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. | 2010 | Pediatr. Nephrol. | pmid:20676692 |
| Wasilewska A et al. | Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. | 2010 | Pediatr. Nephrol. | pmid:20602239 |
| Siomou E et al. | Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. | 2011 | Pediatr. Nephrol. | pmid:21479768 |
| Ketteler M et al. | "Missing" inhibitors of calcification: general aspects and implications in renal failure. | 2005 | Pediatr. Nephrol. | pmid:15549415 |
| Swolin-Eide D et al. | The novel bone alkaline phosphatase B1x isoform in children with kidney disease. | 2006 | Pediatr. Nephrol. | pmid:16932897 |
| Rosso DA et al. | Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. | 2006 | Pediatr. Res. | pmid:16439593 |
| Bargman R et al. | High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. | 2012 | Pediatr. Res. | pmid:22926546 |
| Vidal K et al. | Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. | 2004 | Pediatr. Res. | pmid:15155868 |
| Honsawek S et al. | Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. | 2009 | Pediatr. Surg. Int. | pmid:19184056 |
| Petersson M et al. | Oxytocin stimulates proliferation of human osteoblast-like cells. | 2002 | Peptides | pmid:12126740 |
| Bartold PM et al. | Mechanisms and control of pathologic bone loss in periodontitis. | 2010 | Periodontol. 2000 | pmid:20403105 |
| Nagasawa T et al. | Roles of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. | 2007 | Periodontol. 2000 | pmid:17214836 |
| Wang AY | Vascular and other tissue calcification in peritoneal dialysis patients. | 2009 | Perit Dial Int | pmid:19270239 |
| Nemec K and Schubert-Zsilavecz M | [Future therapies for metabolic bone diseases. New concepts and targets]. | 2001 | Pharm Unserer Zeit | pmid:11715689 |
| Treuheit MJ et al. | Inverse relationship of protein concentration and aggregation. | 2002 | Pharm. Res. | pmid:12033388 |
| Pipes GD et al. | Optimization and applications of CDAP labeling for the assignment of cysteines. | 2005 | Pharm. Res. | pmid:16028006 |